COMMUNIQUÉS West-GlobeNewswire

Basilea reports significantly improved financial results in 2017
27/02/2018
54% increase in total revenue, amounting to CHF 101.5 million Operating loss reduced by 68% to CHF 14.1 million Cash position as of year-end 2017 increased to CHF 310.7 million License and distribution agreements in [...]
Vistin Pharma ASA : Fourth quarter 2017 results
27/02/2018
Oslo, Norway, 27 February 2018 Vistin Pharma had a revenue of NOK 41.6 million in the fourth quarter 2017, compared to NOK 32.5 million in the fourth quarter 2016. Adjusted EBITDA from continuing operations came to [...]
Targovax to present at Biologics World Nordic 2018
27/02/2018
Oslo, Norway, 27 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company will present at the following [...]
Biocartis Group NV: Disclosure of a transparency notification
27/02/2018
PRESS RELEASE : REGULATED INFORMATION 27 February 2018, 07:00 CET Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, [...]
Arcturus Therapeutics Issues Statement Regarding Extraordinary General Meeting of Shareholders
27/02/2018
SAN DIEGO, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT ), a leading RNA medicines company, today announced that, based on the preliminary vote count provided by its transfer agent [...]
BioStem Technologies Inc. Announces Intent to Acquire GIINT
27/02/2018
Pompano Beach, FL, Feb. 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in [...]
Kane Biotech Sues Nestlé
27/02/2018
WINNIPEG, Manitoba, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE ) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced that it has filed a lawsuit against Nestec, Ltd., a/k/a Nestec, [...]
Akorn Issues Statement on Investigation
27/02/2018
LAKE FOREST, Ill., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX ), a leading specialty generic pharmaceutical company, today issued the following statement: “Akorn and Fresenius Kabi AG, with the [...]
DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
26/02/2018
DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients Positive preliminary results support Viaskin Milk's potential as the first treatment for patients suffering from IgE- [...]
DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait
26/02/2018
DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait Les résultats préliminaires sont positifs et Viaskin Milk pourrait être le premier traitement potentiel [...]
DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
26/02/2018
Press Release Montrouge, France, February 26, 2018 DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients Positive preliminary results support Viaskin Milk's potential as the [...]
DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait
26/02/2018
Communiqué de presse Montrouge, France, le 26 février 2018 (22h30 CET) DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait Les résultats préliminaires sont [...]
Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018
26/02/2018
BURLINGTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that it will report its fourth quarter and full year 2017 financial results after the close of the U.S. [...]
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS
26/02/2018
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS GAITHERSBURG, Md. and LYON, France, February 26, 2018 - Emergent BioSolutions Inc. (NYSE: EBS) and [...]
EMERGENT BIOSOLUTIONS ET VALNEVA INITIENT UNE ETUDE CLINIQUE DE PHASE I POUR EVALUER LEUR CANDIDAT VACCIN CONTRE LE VIRUS ZIKA
26/02/2018
EMERGENT BIOSOLUTIONS ET VALNEVA INITIENT UNE ETUDE CLINIQUE DE PHASE I POUR EVALUER LEUR CANDIDAT VACCIN CONTRE LE VIRUS ZIKA GAITHERSBURG, Md. et LYON, France, 26 février 2018 - Emergent BioSolutions Inc. (NYSE: EBS) [...]
Almost Family Reports Fourth Quarter and Full Year 2017 Results
26/02/2018
LOUISVILLE, Ky., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Almost Family, Inc. (NASDAQ: AFAM ), a leading provider of home health and related services, announced today its financial results for the quarter and year ended [...]
Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
26/02/2018
– Strong cash position to support eptinezumab development through approval and commercial launch – – Recently reported pivotal PROMISE 2 top-line data in chronic migraine demonstrates eptinezumab significantly reduced [...]
Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
26/02/2018
GAITHERSBURG, Md. and LYON, France, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to [...]
HTG Announces New Australian Patent for Its Technology
26/02/2018
Patent covers methods of co-detecting mRNA and small non-coding RNA TUCSON, Ariz., Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM ), a provider of instruments, reagents, and services for [...]

Pages